Clinical trial · Observational
Hippo Signaling Pathway Proteins in Gingival Crevicular Fluid of Individuals With Periodontal Disease
Hippo Signaling Pathway Proteins and Their Correlation With Markers of Apoptosis and Bone Metabolism in the Gingival Crevicular Fluid of Individuals With Periodontal Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Periodontal disease is a chronic inflammatory condition of the tooth-supporting tissues in which the host inflammatory response drives the destruction of alveolar bone and periodontal attachment. The Hippo signaling pathway is a conserved regulatory network that controls cell proliferation, apoptosis, and bone homeostasis, but its role in human periodontal disease remains unknown. This observational, case-control study compared the levels of Hippo signaling pathway proteins (YAP, TAZ, MST1, TEAD, LATS1, MAP4K4), the anti-apoptotic protein BCL-2, and the bone metabolism marker alkaline phosphatase (ALP) in gingival crevicular fluid across 75 systemically healthy participants grouped as periodontally healthy, gingivitis, or stage 3 grade B periodontitis. The aim was to determine whether these proteins are differentially expressed across periodontal health and disease states and whether they correlate with markers of apoptosis and bone metabolism.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biomarker Discovery and Validation | — | UNRESOLVED | — |
| Gingivitis and Periodontal Diseases | — | UNRESOLVED | — |
| Pathways | — | UNRESOLVED | — |
| Periodontal Disease | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ELISA Biomarker Analysis | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Periodontally healthy
- description
- Systemically healthy adults with clinically healthy periodontium, defined by probing depth of 3 mm or less, bleeding on probing below 10 percent, no clinical attachment loss, and no radiographic bone loss. Gingival crevicular fluid was collected from non-inflamed sites.
- interventionNames
- Diagnostic Test: ELISA Biomarker Analysis
- label
- Gingivitis
- description
- Systemically healthy adults with gingival inflammation without attachment loss, defined by probing depth of 3 mm or less, generalized bleeding on probing above 30 percent, no clinical attachment loss, and no radiographic bone loss. Gingival crevicular fluid was collected from inflamed sites.
- interventionNames
- Diagnostic Test: ELISA Biomarker Analysis
- label
- Stage 3 grade B periodontitis
- description
- Systemically healthy adults with stage 3 grade B periodontitis, defined by probing depth of 6 mm or more, clinical attachment loss of 5 mm or more, bleeding on probing of 30 percent or more, and radiographic alveolar bone loss extending to the middle or apical third of the root. Gingival crevicular fluid was collected from diseased sites.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Systemically healthy individuals aged 18-65 years * Non-smokers or smoking cessation more than 5 years ago * Healthy group: No history of periodontal disease, ≥20 teeth, probing depth (PD) ≤3 mm at all sites, bleeding on probing (BOP) \<10%, radiographic CEJ-to-alveolar bone crest distance ≤3 mm in ≥95% of teeth * Gingivitis group: No history of periodontal disease, ≥20 teeth, PD ≤3 mm at all sites, BOP ≥30%, radiographic CEJ-to-alveolar bone crest distance ≤3 mm in ≥95% of teeth * Periodontitis group: ≥15 teeth, \>30% of teeth affected by periodontal disease, PD ≥6 mm, clinical attachment loss (CAL) ≥5 mm, vertical bone loss ≥3 mm, Class II or III furcation involvement, radiographic alveolar bone loss extending to the middle third or beyond (≥33%), bone loss-to-age ratio between 0.25 and 1.00 Exclusion Criteria: * Periodontal treatment or antibiotic use within the past 6 months * Fewer than 20 teeth (excluding third molars) * Presence of any systemic disease * Current smoking or cessation within the past 5 years * Use of immunosuppressive medication * Alcohol consumption * Regular medication use * Pregnancy or lactation * Need for antibiotic prophylaxis prior to dental procedures * Prosthetic restorations on the teeth selected for sampling
References
Publications (10)
- BACKGROUNDZheng Y, Pan D. The Hippo Signaling Pathway in Development and Disease. Dev Cell. 2019 Aug 5;50(3):264-282. doi: 10.1016/j.devcel.2019.06.003. PMID 31386861
- BACKGROUNDQian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022 Oct 12;12:985363. doi: 10.3389/fonc.2022.985363. eCollection 2022. PMID 36313628
- BACKGROUNDKegelman CD, Mason DE, Dawahare JH, Horan DJ, Vigil GD, Howard SS, Robling AG, Bellido TM, Boerckel JD. Skeletal cell YAP and TAZ combinatorially promote bone development. FASEB J. 2018 May;32(5):2706-2721. doi: 10.1096/fj.201700872R. Epub 2018 Jan 10. PMID 29401582
- BACKGROUNDJia L, Gu W, Zhang Y, Jiang B, Qiao X, Wen Y. Activated Yes-Associated Protein Accelerates Cell Cycle, Inhibits Apoptosis, and Delays Senescence in Human Periodontal Ligament Stem Cells. Int J Med Sci. 2018 Jul 30;15(11):1241-1250. doi: 10.7150/ijms.25115. eCollection 2018. PMID 30123063
- BACKGROUNDHao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2008 Feb 29;283(9):5496-509. doi: 10.1074/jbc.M709037200. Epub 2007 Dec 24. PMID 18158288
- BACKGROUNDGamonal J, Bascones A, Acevedo A, Blanco E, Silva A. Apoptosis in chronic adult periodontitis analyzed by in situ DNA breaks, electron microscopy, and immunohistochemistry. J Periodontol. 2001 Apr;72(4):517-25. doi: 10.1902/jop.2001.72.4.517. PMID 11338305
- BACKGROUNDFu M, Hu Y, Lan T, Guan KL, Luo T, Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022 Nov 8;7(1):376. doi: 10.1038/s41392-022-01191-9. PMID 36347846